Free tool
FAERS Monitor: Terlivaz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022231 or its brand name (Terlivaz, Terlipressin Acetate). Reports on generic versions are filed under their own applications.
Reports
331
Serious
299
90% of reports
Hospitalization
147
Death reported
95
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective41
- ascites25
- diarrhoea23
- renal impairment20
- off label use18
- acute kidney injury17
- electrocardiogram qt prolonged17
- multiple organ dysfunction syndrome17
- product use in unapproved indication17
- respiratory failure17
- hepatic encephalopathy16
- toxicity to various agents16
- pulmonary oedema14
- drug interaction12
- hepatic failure12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 5 |
| 2006 | 6 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 8 |
| 2013 | 2 |
| 2014 | 14 |
| 2015 | 13 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 9 |
| 2019 | 17 |
| 2020 | 26 |
| 2021 | 26 |
| 2022 | 29 |
| 2023 | 22 |
| 2024 | 24 |
| 2025 | 53 |
| 2026 | 56 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,828 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatic encephalopathySignal | 16 | 109.1 | 67.6 | 1,606 |
| ascitesSignal | 25 | 54.1 | 37.1 | 1,251 |
| multiple organ dysfunction syndromeSignal | 17 | 38.2 | 24.0 | 579 |
| electrocardiogram qt prolongedSignal | 17 | 30.0 | 18.9 | 449 |
| hepatic failureSignal | 12 | 25.3 | 14.5 | 257 |
| pulmonary oedemaSignal | 14 | 19.9 | 11.9 | 233 |
| renal impairmentSignal | 20 | 15.1 | 9.9 | 251 |
| respiratory failureSignal | 17 | 14.8 | 9.3 | 206 |
| acute kidney injurySignal | 17 | 7.1 | 4.4 | 83 |
| toxicity to various agentsSignal | 16 | 6.0 | 3.7 | 63 |
| drug interactionSignal | 12 | 4.8 | 2.8 | 33 |
| product use in unapproved indicationSignal | 17 | 4.4 | 2.7 | 41 |
| diarrhoeaSignal | 23 | 2.3 | 1.5 | 15 |
| drug ineffective | 41 | 2.0 | 1.5 | 20 |
| off label use | 18 | 1.3 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.